

METHOD OF IDENTIFICATION OF A SOLUBLE SET OF BIOMARKERS FOR DIAGNOSIS, PROGNOSIS AND MONITORING OF GLIOBLASTOMA, AND METHOD FOR DIAGNOSIS, PROGNOSIS OR MONITORING OF GLIOBLASTOMA BASED ON THE USE OF THIS SET

Authors: Tanase Cristiana¹, Albulescu Radu Nicolae Aurel¹, Codrici Elena¹, Mihai Simona¹, Albulescu Lucian¹, Popescu Ionela Daniela¹, Constantinescu Ștefan¹


"Victor Babeș" National Institute for Research and Development in the Field of Pathology and Biomedical Sciences, Bucharest

RO130590B1/

30.08.2018

**FIELDS OF APPLICATION:
MEDICINE**

- The invention relates to a method of identification of a set of biomarkers to be used in prognosis and diagnosis of brain tumors.
- According to the invention, the method comprises the simultaneous determination of serum and plasma concentration in samples taken from patients suffering from glioblastoma versus the control of a complex of cytokines and angiogenic factors IL-1 β , IL-6, TNF alpha and VEGF, the values of which are 1.5...10 times higher than the average normal values, and the simultaneous use thereof as a set of biomarkers for monitoring brain tumors.



Fields of application:

Medicine - The technical problem solved by the present invention is the early diagnosis of brain tumors, especially glioblastoma, the precise classification of patients and their post-therapeutic monitoring through the creation and use of a useful and inventive set of circulating protein biomarkers




Figure 1. Shows the change in expression of serum cytokines IL-1b, IL-6, TNF α and VEGF in patients with glioblastoma. Data mean values + standard deviation of the degree of change in concentration compared to the mean serum concentrations at normal.




Figure 2. Shows serum levels of pro-inflammatory cytokines IL-1b, IL-6, TNF α in glioblastoma patients versus controls. Data represent mean values from triplicate analysis + standard deviation $p < 0.05$ (ANOVA).

Figure 3. Shows the values of serum VEGF concentrations in glioblastoma patients and controls, determined by Luminex-xMAP (top) and ELISA (bottom) $p < 0.05$ (ANOVA) methods.